Neos Therapeutics to Present at the UBS Global Healthcare Conference

DALLAS and FORT WORTH, Texas, May 15, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. NEOS, a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies, today announced that Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics, will present a company overview at the upcoming UBS Global Healthcare Conference on Tuesday, May 22, 2018 at 9:30 a.m. ET in New York, NY.

A live webcast of the presentation will be available on the Investor Relations page of the company's website at http://investors.neostx.com/.

About Neos Therapeutics
Neos Therapeutics, Inc. NEOS is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT^® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT^® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex^®1, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is available at www.neostx.com.

¹Tussionex^® is a registered trademark of the UCB Group of Companies.

CONTACTS:

Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com

Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com